Shares of Danish drugmaker Novo Nordisk A/S (NVO) surged over 5% in pre-market trading on Friday following the company's announcement of positive topline results from a Phase 1b/2a clinical trial evaluating its investigational obesity drug amycretin.
The early-stage trial evaluated the safety, tolerability, and weight loss efficacy of once-weekly subcutaneous injections of amycretin, a novel unimolecular GLP-1 and amylin receptor agonist, in 125 individuals with overweight or obesity.
The results showed that amycretin exhibited a favorable safety profile consistent with other incretin-based therapies. More importantly, amycretin led to significant and dose-dependent weight loss, with patients in the highest 20mg dose group achieving an estimated 22% reduction in body weight over 36 weeks of treatment. In comparison, the placebo group experienced only a 2% weight gain over the same period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.